China's Bio-manufacturing Industry Nears RMB 1 Trillion in Scale as Multiple Regions Ramp Up Strategic Investments

9Month26Recently, according to a report by CCTV News, data from the Ministry of Industry and Information Technology indicates that China’s bio-manufacturing industry is experiencing strong growth momentum and continues to lead in competitiveness within the global industrial landscape.

Latest statistical data show that the total scale of China's bio-manufacturing industry has currently approached1trillion yuan, with fermentation production capacity accounting for the world's total70%As a result, a number of competitive biomanufacturing industry clusters have emerged.

Behind the scale of industry and capacity advantages lies the continuous drive of technological innovation.

Over the past five years, China's major biomanufacturing enterprises have cumulatively filed and been granted a total of13680Item,9447items, accounting for % of the total historical applications52.2%and63.8%, the pace of technological innovation has accelerated significantly. Currently, China's biomanufacturing industry has achieved global leadership in certain emerging fields.

He Yaqiong, Director of the Consumer Goods Industry Department under the Ministry of Industry and Information Technology, stated that the most critical breakthrough needed lies in the pilot application and conversion of new achievements into practical scenarios.Regions should develop biomanufacturing in accordance with local conditions, strengthen top-level design for biomanufacturing, and prioritize the provision of supportive policies.

At the same time as the Ministry of Industry and Information Technology released industry data, except for Chongqing, Nanning, and Hefei,Tianjin and Quzhou, Zhejiang, also announced that they will continue to vigorously develop their biomanufacturing sectors.

According to information from the Quzhou Municipal Finance Bureau, the proposed sub-fund investment projects of the Quzhou Municipal Government Industrial Investment Fund have been reviewed and approved by the Leading Group for the Work of the Industrial Investment Fund, completing all investment decision-making procedures. They are now publicly disclosed, with a public notice period of2025Year9Month19Sun.-9Month28Day.

The provisional name of this sub-fund is “Furong Frontier Innovation Fund for Life and Health,” structured as a limited partnership,Fund Size Target2billion yuan, of which the Quzhou Municipal Government Industrial Fund plans to contribute180010,000 yuan, the fund term is3+4+2years, among which3Annual investment period,4Annual Exit Period, Extendable2In [year], the fund manager was Shanghai Furong Investment Co., Ltd.

Investment directions include biopharmaceuticals and synthetic biology., high-end medical devices,IVD, Biomedical Materials, Life and Health+Innovative niche sectors of significant strategic or industrial importance in fields such as artificial intelligence, future life and health technologies, and foundational technologies.

It is understood that,2025Year1In [Month], Zhejiang Province released the "Implementation Plan for Accelerating the Innovative Development of the Synthetic Biology Industry in Zhejiang Province," proposingStrive for2027The total scale of the province's synthetic biology industry reached1500100 million yuan, to establish a globally influential hub for innovative development in the synthetic biology industry.

and strive to achieve by2027In [Year], Zhejiang will foster and develop the synthetic biology sector.5Provincial-level or higher innovation platforms, implementing major science and technology special projects50Item, Form10more than [X] major landmark achievements, achieving breakthroughs in the creation of core microbial strains, the alternative application of fossil-based products, and new drug development, thereby establishing a presence in the fields of pharmaceuticals, chemicals, materials, agriculture, and food.10Flagship products, and cultivate specialized, refined, distinctive, and innovative “Little Giant” enterprises and single-product champions in the synthetic biology industry20home, with the output value of core synthetic biology enterprises reaching200100 million yuan.

In addition to Quzhou,9Month25According to information released by the Tianjin Municipal People's Government, with the support of the Ministry of Science and Technology, the Head Office of Postal Savings Bank of China, and the Head Office of PICC Property and Casualty Company,Tianjin Municipal Science and Technology Bureau, Postal Savings Bank of China Tianjin Branch, PICC Property and Casualty Company Limited Tianjin Branch, College of Finance at Nankai University, Frontier Institute of Synthetic Biology at Tianjin University, and National Center for Technological Innovation in Synthetic Biology jointly established the Joint Laboratory for Sci-Tech Finance in Bio-Manufacturing (Tianjin Base), explore new models and pathways for leveraging technology finance to boost the development of new quality productive forces, and strengthen financial support for major scientific and technological tasks as well as technology-based enterprises.

According to reports, the Tianjin University Institute of Frontier Synthetic Biology and the National Center for Technological Innovation in Synthetic Biology will leverage their technological advantages as national strategic scientific and technological forces in the field of synthetic biology, focusing on industrial planning and specialized policy research for bio-manufacturing, project organization and selection, third-party evaluation, development of standards and specifications, intellectual property, biosafety, and regulatory ethics.Provide specialized research and advisory services。

Nankai University boasts a profound heritage in finance. Leveraging its theoretical strengths from undertaking the National Natural Science Foundation of China’s Major Project, “Fundamental Theories and Empirical Studies on Sci-Tech Finance,” the School of Finance will focus on the innovative design of sci-tech finance instruments, the construction of risk prevention and control systems for sci-tech finance, and the collaborative optimization of policies.Provide specialized research and advisory opinions。

Technological innovation is characterized by high technology intensity, substantial capital investment, elevated risk, and long development cycles, necessitating financial products and services that align with the inherent dynamics of technological advancement.

The Tianjin Branch of Postal Savings Bank of China and the Tianjin Branch of PICC Property and Casualty Company will establish specialized technology finance institutions, coordinate technology finance instruments, and innovate financial products to support major biomanufacturing science and technology projects, technology-based enterprises, research teams, innovation platforms, the industrialization of scientific and technological achievements, and the development of key industrial parks.Provide loans, insurance, settlement,M&A Financing, advisory services, domestic and international business matchmaking, and other diversified relay-style financial services, supporting the entire innovation chain and the full life cycle of technology-based enterprises, thereby providing strong support for the high-quality development of the bio-manufacturing industry.